PMID: 8611373Mar 1, 1996Paper

Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases

British Journal of Cancer
I Soubeyran Coindre J-M

Abstract

Seventy-four post menopausal patients with primary non-metastatic invasive ductal carcinomas of the breast were first treated with tamoxifen alone (30 mg p.o. daily) for 5 months. To study changes induced by tamoxifen, core biopsies before treatment and surgical specimens after hormonal therapy were assayed by immunohistochemistry for oestrogen (ER) and progesterone receptors (PR), pS2, GSTpi and c-erbB2. After tamoxifen, ER and PR significantly decreased in 60 and 44 cases respectively, whereas 11 and 19 cases showed no variation and 2 and 11 cases showed an increase (P<10(-4)). GSTpi and pS2 showed a significant increase in 43 and 41 cases, a decrease in 2 and 21 cases and no variation in 29 and 12 cases (P<10(-4) and P=0.04 respectively). c-erbB-2 showed no significant variation under tamoxifen, increased in only three cases and decreased in 13 cases. No relation was found between these variations and efficiency of hormone therapy. Our results allow a better knowledge of protein expression modifications occurring in breast cancer cells under tamoxifen therapy. They are also more consistent with clone selection rather than with phenotype modification.

Citations

Nov 23, 2000·Cancer Control : Journal of the Moffitt Cancer Center·M J Ellis
May 25, 2011·Breast Cancer Research and Treatment·Atanas IgnatovThomas Kalinski
Jul 28, 2020·Cancers·Esra Küpeli AkkolRaffaele Capasso
Nov 26, 1999·Breast Cancer Research and Treatment·B E Gillesby, T R Zacharewski
Aug 24, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·M BriffodV Le Doussal
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D A BerryL Norton
Nov 29, 2007·International Journal of Cancer. Journal International Du Cancer·Jean-Philippe TheurillatHolger Moch
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F RévillionJ P Peyrat
Mar 20, 2002·Clinical Breast Cancer·J Geisler, P E Lønning

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.